国产固定剂量复合剂治疗肺结核的临床近期效果观察

目的全面评价国产固定剂量复合剂异烟肼利福平吡嗪酰胺／异烟肼利福平（2HRZ／4HR）的抗结核疗效及毒副反应。方法将81例初治菌阳肺结核患者，随机分为治疗组（2HRZ／4HR）和对照组（2HRZ／4HR）观察近期痰菌阴转率、X线病灶改变及不良反应。结果治疗组和对照组2个月痰菌阴转率分别达82．5％和65．7％；满疗程痰菌阴转率各为100．0％和88．6％；胸部X线明显改善，治疗组和对照组病灶吸收分别占92．7％和94．3％，两组空洞闭合率分别为63．2％和62．5％；治疗组和对照组各有2例和4例肝功异常。结论国产固定复合剂是一种安全、高效、易被患者接受、具有推广应用前景的抗结核药物。

Controlled Clinical Study on Efficacy of National Fixed-Dose Compounds in Antituberculosis Chemotherapy

Objective To evaluate the treatment outcome and side-effects of national fixed-dese compounds（2HRZ/4HR）. Methods 81 new bacteriological positive pulmonary tuberculosis patients were divided randomly into treatment group（42 cases）and control（ 39 cases） group. Results The sputum negative conversion rates at the 2nd month in 山e treatment and the controlgroup were 82.5% and 65.7% respectively. And the rates at the end of the chemotherapy were 100.0% and 88.6% respectively. Chest radiography showed remarkable improvement. The resolution of puhnonary lesions in the treatment group and the control group accounted for 92.7% and 94. 3% respectively,The Cavity closure rates were 63.2% in the treatment group and 62.5% in the control group. Two patients defaulted because of hepatic dysfunction in the treatment group and 4 patients in the control＇s. Conclusion National fixed-dose compounds rifater/rifinah show excellent therapeutic efflcacy,safety and compliance in antituberculous chemotherapy,which could be recommended for wider use in tuberculosis control in China.